Hasan AN, Doubrovina E, Sottile R, Prockop S, Klatt MG, Heller G, Selvakumar A, Barnett L, Hsu KC, O’Reilly RJ. Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T-cells in adoptive therapy. Blood Adv. 2022 May 23:bloodadvances.2022007005. doi: 10.1182/bloodadvances.2022007005. Epub ahead of print.Petersdorf EW, McKallor C, Malkki M, He M, Spellman S, Hsu KC, Strong R, Gooley TA, Stevenson PA. Role of NKG2D Ligands and Receptor in Haploidentical Related Donor Hematopoietic Cell Transplantation. Blood Adv. 2023 Feb 10:bloodadvances.2022008922. doi: 10.1182/bloodadvances.2022008922. Epub ahead of print.van der Ploeg K, Sottile R, Kontopoulos T, Shaffer BC, Papanicolaou GA, Maloy MA, Cho C, Robinson KS, Perales MA, Le Luduec JB, Hsu KC. Emergence of human CMV-induced NKG2C+ NK cells is associated with CD8+ T-cell recovery after allogeneic HCT. Blood Adv. 2023 Oct 10;7(19):5784-5798. doi: 10.1182/bloodadvances.2022008952. PMCID: PMC10561005.Shahid S, Ceglia N, Le Luduec JB, McPherson A, Spitzer B, Kontopoulos T, Bojilova V, Panjwani MK, Roshal M, Shah SP, Abdel-Wahab O, Greenbaum B, Hsu KC. Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia. Blood Adv. 2023 Sep 12;7(17):5069-5081. doi: 10.1182/bloodadvances.2022009468. PMCID: PMC10471937.Santosa EK, Kim H, Rückert T, Le Luduec JB, Abbasi AJ, Wingert CK, Peters L, Frost JN, Hsu KC, Romagnani C, Sun JC. Control of nutrient uptake by IRF4 orchestrates innate immune memory. Nat Immunol. 2023 Oct;24(10):1685-1697. doi: 10.1038/s41590-023-01620-z. Epub 2023 Sep 11.Panjwani MK, Grassmann S, Sottile R, Le Luduec JB, Kontopoulos T, van der Ploeg K, Sun JC, Hsu KC. Single-Cell Profiling Reveals a Naive-Memory Relationship between CD56 bright and Adaptive Human Natural Killer Cells. bioRxiv [Preprint]. 2023 Sep 24:2023.09.23.559062. doi: 10.1101/2023.09.23.559062. PMID: 37790504; PMCID: PMC10543008.Wu Z, Park S, Lau CM, Zhong Y, Sheppard S, Sun JC, Das J, Altan-Bonnet G, Hsu KC. Dynamic variability in SHP-1 abundance determines natural killer cell responsiveness. Sci Signal. 2021 Nov 9;14(708):eabe5380. doi: 10.1126/scisignal.abe5380. Epub 2021 Nov 9.Wu Z, Lau CM, Sottile R, Le Luduec JB, Panjwani MK, Conaty PM, Srpan K, Laib Sampaio K, Mertens T, Adler SP, Hill AB, Barker JN, Cheung NV, Sun JC, Hsu KC. Human Cytomegalovirus Infection Promotes Expansion of a Functionally Superior Cytoplasmic CD3+ NK Cell Subset with a Bcl11b-Regulated T Cell Signature. J Immunol. 2021 Nov 15;207(10):2534-2544. doi: 10.4049/jimmunol.2001319. Epub 2021 Oct 8. PMCID: PMC8578400.Sottile R, Panjwani MK, Lau CM, Daniyan AF, Tanaka K, Barker JN, Brentjens RJ, Sun JC, Le Luduec JB, Hsu KC. Human cytomegalovirus expands a CD8+ T cell population with loss of BCL11B expression and gain of NK cell identity. Sci Immunol. 2021 Sep 24;6(63):eabe6968. doi: 10.1126/sciimmunol.abe6968. Epub 2021 Sep 24.Schetelig J, Baldauf H, Koster L, Kuxhausen M, Heidenreich F, de Wreede LC, Spellman S, van Gelder M, Bruno B, Onida F, Lange V, Massalski C, Potter V, Ljungman P, Schaap N, Hayden P, Lee SJ, Kröger N, Hsu K, Schmidt AH, Yakoub-Agha I, Robin M. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia. Front Immunol. 2021 Jan 19;11:584520. doi: 10.3389/fimmu.2020.584520. PMCID: PMC7851088.Boudreau JE, Giglio F, Gooley TA, Stevenson PA, Le Luduec JB, Shaffer BC, Rajalingam R, Hou L, Hurley CK, Noreen H, Reed EF, Yu N, Vierra-Green C, Haagenson MD, Malkki M, Petersdorf EW, Spellman S, Hsu KC. KIR3DL1/HLA-B subtypes govern AML relapse after hematopoietic cell transplantation. J Clin Onc. 2017. 35(20):2268-2278.Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu Z-H, Spellman SR, Lee SJ, Verneris MR, Hsu K, Fleischhauer K, Cutler C, Antin JH, Neuberg D, Ebert BL. Genetic alterations predict outcomes in patients with myelodysplastic syndrome receiving allogeneic hematopoietic stem cell transplantation. N Engl J Med. 2017. 376:536-547.Shaffer BC and Hsu KC. How important is NK alloreactivity and KIR in allogeneic transplantation? Best Practice & Research Clinical Haematology. 2016.Boudreau JE, Liu X-R, Zhao Z, Zhang A, Shultz LD, Greiner DL, Dupont B, Hsu KC. Cell-extrinsic MHC class I molecule engagement augments NK cell education programmed by cell-intrinsic MHC class I. Immunity. 2016. 45(2):280-9.Shaffer BC, Le Ludec JB, Forlenza C, Jakubowski AA<, Perales MA, Young JW, Hsu KC. Phase II study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016. 22(4): 705-9.Boudreau JE, Mulrooney TJ, Le Luduec J-B, Barker E, Hsu KC. KIR3DL1 and HLA-B density and binding calibrate NK education and response to HIV. J Immunol. 2016 [Epub ahead of print].ForlenzaCJ, BoudreauJE, ZhengJ, ChamberlainE,HellerG, CheungNV, Hsu KC. KIR3DL1 allelic polymorphism and HLA-Bw4 epitopes modulate response to anti-GD2 monoclonal antibody in patients with neuroblastoma. J Clin Oncol. 2016. 34(21):2443-51.Mulrooney TJ, Zhang AC, Goldgur Y, Boudreau JE, Hsu KC. KIR3DS1-Specific D0 Domain Polymorphisms Disrupt KIR3DL1 Surface Expression and HLA Binding. Journal of immunology (Baltimore, Md. : 1950). 2015.Tarek N, Gallagher MM, Chou JF, Lubin MN, Heller G, Barker JN, Hsu KC. KIR and HLA genotypes have no identifiable role in single-unit dominance following double-unit umbilical cord blood transplantation. Bone marrow transplantation. 2015; 50(1):150-2. NIHMSID: NIHMS621302.Boudreau JE, Le Luduec JB, Hsu KC. Development of a novel multiplex PCR assay to detect functional subtypes of KIR3DL1 alleles. PloS one. 2014; 9(6):e99543.Avigan D, Hari P, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Hsu KC. Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013; 19(12):1661-9. NIHMSID: NIHMS534106.Tarek, N, Gallagher MM, Zheng J, LeLuduec JB, Venstrom JM, Chamberlain E, Modak S, Heller G, Dupont B, Cheung NK, Hsu KC. Unlicensed natural killer cells target neuroblastoma following anti-GD2 antibody treatment. J. Clin. Invest. 2012; 122: 3260-3270.Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, Petersdorf E, Dupont B, Hsu KC. HLA-C-dependent prevention of leukemia relapse by donoractivating KIR2DS1. N Engl J Med. 2012; 367:805-816.Venstrom JM, Gooley TA, Spellman S, Pring J, Malkki M, Dupont B, Petersdorf E, Hsu KC. Donor activating KIR3DS1 is associated with decreased acute GvHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood. 2010; 115: 3162-3165.Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, Cheung IY, Dupont B, O’Reilly RJ, Cheung NV, Hsu KC. KIR and HLA Genotypes are associated with improved survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Canc Res. 2009; 15: 7330-7334. *Article highlighted in Nature Reviews Clinical Oncology, Jan 2010.Yu J, Venstrom JM, Liu XR, Pring J, Hasan RS, O’Reilly RJ, Hsu KC. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function following T-cell depleted allogeneic hematopoietic cell transplantation. Blood. 2009; 113: 3875-3884.Ostronoff F, Perales M-A, Stubblefield MD, Hsu KC. Rituximab-responsive Guillain-Barre Syndrome following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008; 42: 71-2.Yu J, Heller G, Chewning JH, Kim S, Yokoyama W, Hsu KC. Diversity and hierarchy of the human natural killer cell response are determined by inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol. 2007; 179: 5977-89.Hsu KC, Pinto-Agnello C, Gooley T, Malkki M, Dupont B, Petersdorf EW, IHWG HCT-KIR Component, Hematopoietic stem cell transplantation: killer immunoglobulin-like receptor component. Tissue Antigens 2007; 69 Suppl. 1: 1-4.Hsu KC, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon J, Bornauser M, Christiansen F, Gratwohl A, Morishima Y, Oudshoorn M, Ringden O, van Rood JJ, Petersdorf E, International Histocompatibility Working Group. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrrow Transpl. 2006; 12: 828-836.Hsu KC, Taylor CA, O’Reilly RJ, Horowitz MM, Arkun K, Pinto C, Dupont B. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105: 4878-4884.Hsu KC, Liu X, Selvakumar A, Mickelson E, O’Reilly RJ, Dupont B. Killer Ig-like receptor (KIR) haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol 2002; 169:5118-5129. Book traversal links for The Katharine Hsu Lab Previous Featured News